drugset / Trial / NCT06956521

Intra-Arterial Magnesium Therapy After Mechanical Thrombectomy in Acute Ischemic Stroke

NCT06956521

Phase 1 Not yet recruiting 30 enrolled Baylor College of Medicine
Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this Phase I unblinded, dose-escalation trial is to evaluate the safety and tolerability of intra-arterial magnesium sulfate injection after mechanical thrombectomy in patients experiencing acute ischemic stroke. This trial is one of the first trials to look at IA administration of magnesium sulfate into at risk brain tissue in a selective and localized fashion.

Timeline

Start
2025-06
Primary completion
2026-06
Completion
2026-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Sulfate Other / unclassified 0.25 g Intrathecal
Subject Magnesium Sulfate Other / unclassified 0.5 g Intrathecal
Subject Magnesium Sulfate Other / unclassified 1 g Intrathecal
Subject Magnesium Sulfate Other / unclassified 1.5 g Intrathecal

Indications